Back to Journals » Biologics: Targets and Therapy » Volume 7

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

Authors Ansari J, Hussain S, Ansari A, Glaholm J

Received 21 August 2012

Accepted for publication 22 November 2012

Published 28 February 2013 Volume 2013:7 Pages 39—46


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Jawaher Ansari,1 Syed A Hussain,2 Asif Ansari,3 John Glaholm4

1Beatson West of Scotland Cancer Centre, Glasgow, UK; 2Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK; 3Cleveland Clinic, Cleveland, Ohio, USA; 4University Hospital Birmingham NHS Trust, Edgbaston, Birmingham, UK

Abstract: A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC, the ideal sequencing of these agents remains unclear.

Keywords: metastatic RCC, vascular endothelial growth factor receptor inhibitor, molecular targeted agent, clear-cell carcinoma

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.